An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder

Ravulizumab improves on eculizumab's success as a highly effective NMOSD therapy by decreasing infusion frequency, thereby increasing patient convenience. We predict that ravulizumab will eventually replace eculizumab but may not have a similar impact on inebelizumab or satralizumab. Patients taking C5 complement inhibitors have an increased risk of serious meningococcal infections, such as invasive meningococcal disease (IMD), and have incomplete protection against IMD despite immunization. Thus, we recommend that in addition to standard pre-immunizations against <i>Neisseria meningitidis</i>, patients should also be assessed for starting on appropriate antibiotic prophylaxis against IMD, based on local resistance patterns.